BioSpace News Archive

Glioblastoma is the most aggressive type of brain cancer, with an average survival of only 14 to 16 months after diagnosis.

Amgen (NASDAQ:AMGN) today announced the presentation of new data across its broad oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2023, taking place from October 20-24 in Madrid.

Matica Biotechnology, Inc. announced the appointment of four experienced leaders in biotechnology and the life sciences to its board of advisors: Charlene Banard, Gerard Fleury, Evan Greger, and Carson Sublett.

Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter) announced that the clinical results of first-in-human study of FGFR4 inhibitor Irpagratinib（ABSK011）and the clinical results of first-in-human dose-escalating of PD-L1 inhibitor ABSK043 with advanced solid tumors will be presented at the 2023 European Society for Medical Oncology（ESMO）annual meeting to be held in Spain, from October 20 to 24, 2023.

Today, GE HealthCare (Nasdaq: GEHC) announced US FDA 510(k) clearance of Allia IGS Pulse - the latest addition to the company’s image guided system (IGS) offerings.

The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the U.S. Food and Drug Administration (FDA) decision to expand eligibility of Bristol Myers Squibb’s Opdivo (nivolumab) to include patients with completely resected Stage IIB and IIC melanoma.

The International Union for Conservation of Nature (IUCN), Standards and Petitions Committee has accepted the National Association for Biomedical Research (NABR) formal petition challenging the IUCN’s 2022 designation of long-tailed macaques

Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has made in cash the final maturity date payment of C$51.1 million (or approximately US$37.5 million) to Computershare Trust Company of Canada as trustee for holders of Medexus’s

BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, is pleased to announce a second partnership with the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services.

SAIL Fusion, a medical device company focused on advancing the surgical treatment of sacroiliac joint dysfunction through solutions built upon AO principles, announced that it has conducted the first implantations of its novel BowTie SI Fusion System.